EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Online Adaptive MR-Guided Ultrahypofractionated Radiotherapy of Prostate Cancer on a 1.5 T MR-Linac: Clinical Experience and Prospective Evaluation

Vlatko Potkrajcic iD, Cihan Gani iD, Stefan Georg Fischer, Simon Boeke, Maximilian Niyazi, Daniela Thorwarth, Otilia Voigt, Moritz Schneider iD, David Mönnich iD, Sarah Kübler, Jessica Boldt, Elgin Hoffmann und 3 weitere

Current Oncology · 2024

DOI: 10.3390/curroncol31050203 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Current Oncology, 2024. Verfasst von Vlatko Potkrajcic und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, University Hospital Tübingen, 72076 Tuebingen, Germany. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Radiotherapy, Image-Guided. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: German Research Council (DFG), grants no. MU 4603/1-1 (PAK 997/1) and ZI 736/2-1., German Research Council (DFG).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The use of hypofractionated radiotherapy in prostate cancer has been increasingly evaluated, whereas accumulated evidence demonstrates comparable oncologic outcomes and toxicity rates compared to normofractionated radiotherapy. In this prospective study, we evaluate all patients with intermediate-risk prostate cancer treated with ultrahypofractionated (UHF) MRI-guided radiotherapy on a 1.5 T MR-Linac within our department and report on workflow and feasibility, as well as physician-recorded and patient-reported longitudinal toxicity. A total of 23 patients with intermediate-risk prostate cancer treated on the 1.5 T MR-Linac with a dose of 42.7 Gy in seven fractions (seven MV step-and-shoot IMRT) were evaluated within the MRL-01 study (NCT04172753). The duration of each treatment step, choice of workflow (adapt to shape-ATS or adapt to position-ATP) and technical and/or patient-sided treatment failure were recorded for each fraction and patient. Acute and late toxicity were scored according to RTOG and CTC V4.0, as well as the use of patient-reported questionnaires. The median follow-up was 12.4 months. All patients completed the planned treatment. The mean duration of a treatment session was 38.2 min. In total, 165 radiotherapy fractions were delivered. ATS was performed in 150 fractions, 5 fractions were delivered using ATP, and 10 fractions were delivered using both ATS and ATP workflows. Severe acute bother (G3+) regarding IPS-score was reported in five patients (23%) at the end of radiotherapy. However, this tended to normalize and no G3+ IPS-score was observed later at any point during follow-up. Furthermore, no other severe genitourinary (GU) or gastrointestinal (GI) acute or late toxicity was observed. One-year biochemical-free recurrence survival was 100%. We report the excellent feasibility of UHF MR-guided radiotherapy for intermediate-risk prostate cancer patients and acceptable toxicity rates in our preliminary study. Randomized controlled studies with long-term follow-up are warranted to detect possible advantages over current state-of-the-art RT techniques.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsRadiotherapy, Image-GuidedHumansMaleProspective StudiesAgedMiddle AgedMagnetic Resonance ImagingRadiation Dose HypofractionationAged, 80 and over

Stichwörter der Autor:innen

MR-Linachypofractionated radiotherapyprostate cancer

Autor:innen und Institutionen

  • Department of Radiation Oncology, University Hospital Tübingen, 72076 Tuebingen, Germany.
  • Department of Radiation Oncology, Klinikum Esslingen, 73730 Esslingen am Neckar, Germany.
  • Section for Biomedical Physics, Department of Radiation Oncology, University Hospital Tübingen, 72076 Tuebingen, Germany.
  • Department of Radiation Oncology and Radiotherapy, RKH-Kliniken Ludwigsburg, 71640 Ludwigsburg, Germany.
  • Department of Radiation Oncology, Alb-Fils Kliniken GmbH, 73035 Goeppingen, Germany.

ORCID-Profile: Vlatko Potkrajcic, Cihan Gani, Moritz Schneider, David Mönnich, Daniel Wegener

Förderung

  • German Research Council (DFG), grants no. MU 4603/1-1 (PAK 997/1) and ZI 736/2-1.
  • German Research Council (DFG)

Zitieren

APA

Potkrajcic, V., Gani, C., Fischer, S. G., Boeke, S., Niyazi, M., Thorwarth, D., Voigt, O., Schneider, M., Mönnich, D., Kübler, S., Boldt, J., Hoffmann, E., Paulsen, F., Mueller, A. C., & Wegener, D. (2024). Online Adaptive MR-Guided Ultrahypofractionated Radiotherapy of Prostate Cancer on a 1.5 T MR-Linac: Clinical Experience and Prospective Evaluation. Current Oncology. https://doi.org/10.3390/curroncol31050203

Vancouver

Potkrajcic V, Gani C, Fischer SG, Boeke S, Niyazi M, Thorwarth D, et al. Online Adaptive MR-Guided Ultrahypofractionated Radiotherapy of Prostate Cancer on a 1.5 T MR-Linac: Clinical Experience and Prospective Evaluation. Current Oncology. 2024. doi:10.3390/curroncol31050203

BibTeX
@article{Potkrajcic2024,
  author = {Potkrajcic, Vlatko and Gani, Cihan and Fischer, Stefan Georg and Boeke, Simon and Niyazi, Maximilian and Thorwarth, Daniela and Voigt, Otilia and Schneider, Moritz and Mönnich, David and Kübler, Sarah and Boldt, Jessica and Hoffmann, Elgin and Paulsen, Frank and Mueller, Arndt-Christian and Wegener, Daniel},
  title = {Online Adaptive MR-Guided Ultrahypofractionated Radiotherapy of Prostate Cancer on a 1.5 T MR-Linac: Clinical Experience and Prospective Evaluation},
  journal = {Current Oncology},
  year = {2024},
  doi = {10.3390/curroncol31050203}
}
Kostenlos starten →